Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0U0EC
|
|||
Drug Name |
TRemelimumab + MEDI0562
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
Company |
MedImmune Gaithersburg, MD
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | Agonist | [1] |
OX40L receptor (CD134) | Target Info | Agonist | [1] | |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
T cell receptor signaling pathway | ||||
Autoimmune thyroid disease | ||||
Rheumatoid arthritis | ||||
Cytokine-cytokine receptor interaction | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Wnt Signaling Pathway | ||||
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
Downstream signaling in naï | ||||
Reactome | CTLA4 inhibitory signaling | |||
TNFs bind their physiological receptors | ||||
WikiPathways | Vitamin D Receptor Pathway | |||
T-Cell Receptor and Co-stimulatory Signaling | ||||
Allograft Rejection | ||||
Costimulation by the CD28 family |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.